Navigation Links
Cost-effectiveness of cetuximab in metastatic colorectal cancer
Date:8/7/2009

From a health-care system perspective, it may be more efficient to use the drug cetuximab only in colorectal cancer patients whose tumors have a wild-type KRAS gene, according to a study published online August 7 in the Journal of the National Cancer Institute.

Earlier, patients whose tumors harbored wild-type KRAS were found to have a higher survival advantage when treated with cetuximab in a randomized trial by the National Cancer Institute of Canada Clinical Trials Group.

In this study, Nicole Mittmann, of the HOPE Research Centre Sunnybrook Health Sciences Centre, in Toronto, and colleagues used prospectively collected resource utilization and health utility data from that trial to conduct a cost-effectiveness analysis to determine the costs per life-year gained and costs per quality-adjusted life-year gained.

Mean survival times for the study arms were calculated over an 18- to 19-month period for all patients in the study and for patients whose tumors had wild-type KRAS.

For all patients, cetuximab showed very high (i.e., unfavorable) incremental cost-effectiveness ratiosmeaning it was very costly in relation to benefitscompared with best supportive care. The incremental cost-effectiveness ratios were, however, more favorable for patients whose tumors harbored wild-type KRAS.

"Consequentlyit would not be efficient to fund cetuximab treatment for all patients with advanced colorectal cancer," the authors write. "Use of cetuximab may be restricted based on a patient's tumor KRAS status."

In an accompanying editorial, Robin Yabroff, Ph.D., of the Division of Cancer Control and Population Science, National Cancer Institute in Bethesda, Md., and Deborah Schrag, M.D., of the Dana Farber Cancer Institute in Boston, note that these findings help raise important questions about how cost-effectiveness analyses inform coverage decisions.

Ideally, personalization of cancer therapy could save money by avoiding treatment for patients with KRAS mutations who do not respond to cetuximab, according to the editorialists. However, this study shows that even when restricted to metastatic colorectal cancer patients with wild-type KRAS tumors, the cost-per quality adjusted life year gained for cetuximab therapy compared to best supportive care exceeds commonly accepted thresholds of $50,000 to $100,000 per quality adjusted life year that signify "good value" health care interventions.

Given current attention to healthcare costs in the U.S., interest in explicitly comparing the costs and benefits of treatment, as performed by Mittmann et al. in Canada, is likely to increase. "The sustainability of the current approach to decision-making about coverage is unclear, particularly in light of escalating health care costs," the editorialists write.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
2. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
3. Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy
4. Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
5. Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells
6. Researchers identify new method to selectively kill metastatic melanoma cells
7. Chicago team uses artificial intelligence to diagnose metastatic cancer
8. Smoking increases potential for metastatic pancreatic cancer
9. Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen
10. Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
11. 2-drug combination appears safe and active in metastatic kidney cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: